AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie reported FY2025 revenue of about $61.2 billion, up 9%, and is projected to grow sales to $67.2 billion while net income rises sharply from $4.2 billion to $14.6 billion this year, supported by Skyrizi, Rinvoq and its Apogee Therapeutics acquisition. Johnson & Johnson generated $94.2 billion of FY2025 revenue (+6%) and $26.8 billion of net income, with revenue expected to reach $101 billion, underpinned by its Innovative Medicine and MedTech businesses. AbbVie trades at a lower 18.8x forward P/E versus J&J's 23.5x, but carries greater patent-expiry, product-concentration and balance-sheet risks; J&J offers stronger diversification and profitability but faces talc litigation and Orthopedics separation costs.

Analysis

ABBV’s valuation discount is better understood as a duration and execution discount than a simple growth opportunity. The investment case now depends on whether Skyrizi/Rinvoq and neuroscience assets can replace mature-product cash flows fast enough to protect dividend growth while funding business-development spending; an FDA win in Parkinson’s would improve the narrative but is unlikely to be financially material in the first 12 months. The reported Apogee transaction should be independently verified before assigning any value, particularly because early-stage immunology acquisitions typically add R&D expense and contingent-value risk well before revenue.

JNJ offers a cleaner earnings-quality setup: MedTech can cushion pharma-specific pricing and patent shocks, while the Orthopedics separation creates a potential 6-18 month rerating catalyst if the remaining portfolio receives a higher-growth multiple. The counterweight is that a separation can expose stranded costs and reduce diversification benefits; talc-reserve developments remain the more binary multiple driver. ABBV’s negative book equity is not itself a solvency signal given acquisition accounting and capital returns, but its lower liquidity flexibility makes incremental M&A or a pipeline disappointment more consequential than for JNJ.

Near term, neither name has an obvious information edge from this comparison alone. Over 1-3 months, ABBV is more sensitive to regulatory decisions, prescription-trend data, and any reset in management’s long-term sales bridge; JNJ is more sensitive to litigation resolution mechanics and confirmation of post-separation margin targets. Contrarian view: the market may be underpricing JNJ’s ability to redeploy MedTech capital into higher-return categories after the carve-out, while overstating the value of ABBV’s headline pipeline optionality before probability-adjusted sales and launch investment are visible.

Key Decisions for Investors

• Prefer a 6-12 month pair trade: long JNJ / short ABBV in equal dollar amounts. It isolates balance-sheet and earnings-duration quality from broad healthcare beta; target 8-12% relative return, with stop/review if ABBV raises its post-2027 revenue outlook by more than 5% or JNJ’s talc liability framework deteriorates materially.
• Do not add directional ABBV exposure ahead of the Parkinson’s FDA event without verifying the indication, review date, label economics, and the claimed Apogee transaction terms. Treat confirmation of commercially meaningful peak-sales guidance and durable Skyrizi/Rinvoq demand as a trigger to reassess a long rather than as an immediate catalyst trade.
• For existing ABBV longs, hedge 3-6 month event risk with put spreads rather than reducing the core position if the goal is dividend exposure; downside protection is warranted if guidance implies higher R&D/M&A funding or slower immunology growth. Falsification: a quarterly cut to long-range earnings or free-cash-flow conversion expectations.
• Monitor MCK and CAH as second-order signals, not shorts: sustained margin pressure or working-capital stress at distributors would matter more for ABBV given its concentrated U.S. channel exposure. A change in distributor contract economics or inventory days is the relevant alert.